Celldex Therapeutics, Inc. CLDX
31.24 USD +1.37 (+4.59%)
At closeNov 9, 2026, 4:00 PM EST
31.24 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
29.42 Day range 31.66
22.10 52-week range 45.14
- YTD
- +15.02%
- 1 year
- +36.42%
News
marketbeat.com Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results Celldex Therapeutics NASDAQ: CLDX plans to submit a biologics license application for barzolvolimab in 2027, using full 52-week data from its Phase 3 studies in chronic spontaneous urticaria,…
benzinga.com Canaccord Genuity Maintains Buy on Celldex Therapeutics, Raises Price Target to $68 Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $68.
benzinga.com Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $61 Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $57 to $61.- benzinga.com Celldex Therapeutics Q3 EPS $(0.96) Beats $(1.02) Estimate Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.96) per share which beat the analyst consensus estimate of $(1.02) by 5.88 percent. This is a 4.95 percent increase over losses of…
globenewswire.com Celldex to Present at Upcoming Investor Conferences HAMPTON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming investor conferences: The Guggenheim 3rd…- benzinga.com HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $64 price target.
benzinga.com Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88 Leerink Partners analyst Thomas Smith maintains Celldex Therapeutics (NASDAQ:CLDX) with a Outperform and raises the price target from $70 to $88.
benzinga.com Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57 Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $50 to $57.
benzinga.com Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
benzinga.com Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.
benzinga.com HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64 HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $42 to $64.
benzinga.com Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72 Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $61 to $72.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose…- benzinga.com Celldex Reports Topline Results From The Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Trials Evaluating Two Doses Of Barzolvolimab In Patients With Chronic Spontaneous Urticaria; Results Showed Rapid, Profound, Sustained Efficacy, Supporting Barzolvolimab’s Potential To Be A Transformational Therapy In CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groupsClinically meaningful and statistically significant benefit demonstrated in…
benzinga.com Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50 Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $46 to $50.- benzinga.com Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46 Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.
- benzinga.com Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53 Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.
- benzinga.com Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses…
- benzinga.com Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72 Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $72.
- benzinga.com Wells Fargo Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $48 Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $54 to $48.
- benzinga.com Morgan Stanley Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $40 Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $44 to $40.
benzinga.com Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.
benzinga.com Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $61 Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $67 to $61.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Celldex Presents Additional Results From Phase 2 Clinical Sturies Of Barzolvolimab In Chronic Spontaneous Urticaria And Cold Urticaria And Symptomatic Dermographism At 2026 Allergy, Asthma & Immunology's Annual Meeting Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic…
benzinga.com Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.- benzinga.com Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 275 companies made new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 1214 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 422 stocks made new 52-week lows.
- benzinga.com 77 Biggest Movers From Yesterday Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an…
- benzinga.com Earnings Scheduled For February 28, 2022 Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 17, 2021 Upgrades
- benzinga.com Stocks That Hit 52-Week Highs On Thursday Before 10 a.m. ET on Thursday, 91 companies hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday On Thursday morning, 159 companies achieved new highs for the year.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday Before 10 a.m. ET on Tuesday, 128 companies hit new 52-week highs.
- benzinga.com 58 Biggest Movers From Yesterday Gainers MediaCo Holding Inc. (NASDAQ: MDIA) shares jumped 311.6% to close at $17.00 on Monday after jumping 20% on Friday.
- benzinga.com Stocks That Hit 52-Week Highs On Monday This morning 161 companies reached new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Friday This morning 143 companies set new 52-week highs.